Peyronie’s disease is a chronic inflammatory condition of the corpora cavernosa characterized by the formation of plaque in the tunica albuginea, which results in penile deformity. Conservative medical approaches encompass oral, topical, and physical treatment. Only two cases of patients with Peyronie’s disease with complete plaque regression after treatment have been described in literature.
Case presentation
Case 1: A 50-year-old Caucasian man with penile pain and double penile curvature of 5° (left ventrolateral), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants + topical diclofenac gel). At follow-up after over 4 years of treatment, the patient no longer complained of any penile deformity or pain. Ultrasound examination did not show any plaque. Case 2: A 26-year-old Caucasian man with lateral-right penile curvature of 30° (previous congenital curvature of 15°), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants + topical diclofenac gel + penile injections/pentoxifylline). After 28 months of treatment, the patient presented a lateral right curve of 15° at follow-up, similar to the original congenital penile curvature. Ultrasound examination no longer showed any plaque. Case 3: A 36-year-old Caucasian man with penile pain and a complex penile curvature of 15° and 20° (left dorsolateral), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants + topical diclofenac gel + penile injections/pentoxifylline). At follow-up after 28 months of treatment, the patient presented a dorsal curve (10°) similar to the original congenital curvature. Penile palpation did not detect any nodules, and ultrasound no longer showed any plaque.
Conclusions
This study demonstrates that our multimodal therapy is able to completely regress plaque, as demonstrated in our previously published article. Peyronie’s disease has the potential to be treated conservatively with good results. However, this method of treatment needs to be combined with accurate ultrasound assessment, performed using a sufficiently advanced machine by an experienced operator.
Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Background
Peyronie’s disease (PD) is a chronic inflammatory condition of the corpora cavernosa characterized by the formation of fibrous or calcified plaque in the tunica albuginea, resulting in penile deformity (for example curvature, divots, hourglass deformity). Patients suffering from PD present with penile pain (20–70%), penile deformity (94%), and erectile dysfunction (over 30%) [1, 2]; depression (48%) [3]. Although the origin of PD is still not completely understood, trauma—including micro-injuries—is postulated to be its most likely cause [4]. As fibrin accumulates in the site of the trauma, it triggers an inflammatory response involving an overproduction of fibrogenic cytokines and free radicals [5‐8]. Conservative approaches encompass oral therapy with colchicine, potassium para-aminobenzoate, tamoxifen, antioxidants, phosphodiesterase-5 inhibitors, and so on; topical therapy consisting of injections with verapamil, corticosteroids, Clostridium histolyticum collagenase, interferon-α2b (IFNa2b), hyaluronic acid, pentoxifylline (PTX); and physical therapy (vacuum devices and/or penile traction devices, iontophoresis, extracorporeal shock wave therapy (ESWT), and so on) [9, 10]. A multimodal treatment combines various therapeutic agents, as well as different forms of administration (for example oral therapy and injections), and does not rule out concurrent use of physical treatment options such as iontophoresis, penile extenders, vacuum devices, and ESWT. A combination of treatment approaches can offer better outcomes than a single substance or therapy [11].
This paper presents three cases of PD patients treated with a multimodal antioxidant therapy (including oral antioxidants, topical diclofenac gel + penile-injections/pentoxifylline) at our Peyronie’s Care Center. The three patients achieved complete regression of the area affected by disease. This is the second article describing the complete plaque regression achieved in patients with PD.
Anzeige
Case reports
Case 1
A 50-year-old Caucasian male, non-smoker, with normal body weight, presented to our clinic in July 2014 complaining of mild penile pain during erection and penile curvature with onset about 6 months before. The visual analogue pain score (VAS) was 2 (score from 0 to 10). Subjective assessment of erection, evaluated using the International Index of Erectile Function (IIEF) questionnaire, provided a score of 27. When administering the IIEF questionnaire, we took into consideration questions 1, 2, 3, 4, 5, and 15, which specifically refer to erectile function (normal range from 26 to 30). The penile deformity consisted of both a ventral curvature, with a 5° angle, and a lateral left curvature of 5°. On palpation at the distal third of the penis, physical examination revealed a nodule measuring about 20 mm in length. The patient underwent a physical examination and penile Doppler ultrasound (alprostadil 10 mcg). The volume of the plaque was measured in its three dimensions using the ellipsoid formula (volume = 0.524 × length × width × thickness) [12, 13].
Cavernous artery flow and end-diastolic velocity were normal: peak systolic velocity was 74 cm/seconds (bilaterally); end-diastolic velocity was 0 cm/seconds (bilaterally). The penile plaque was located ventrally and at the distal third of the penis; its ultrasound aspect was iso-hypoechoic and it measured 25.2 × 12.7 × 4.37 mm (volume = 733 mm3). Within the plaque there was a calcification measuring 15.1 × 4.0 mm (Fig. 1, see Table 1 ).
Fig. 1
Penile ultrasound prior to treatment. A Plaque measurement in longitudinal and transverse scan. B Calcification measurement in longitudinal scan
Table 1.
Case summaries of three patients with Peyronie’s disease treated by combined multimodal therapy
No.
Patient age
Comorbidities
Penile plaque site
Ultrasound measurements (length × width × thickness) and plaque volume (A) before and (B) after treatment
Type of deformity (A) initial and (B) after treatment
Pain score/VAS scale (1–10)
IIEF score before and after treatment
Total duration of treatment until plaque regression
Complete combined multimodal treatment
1
50 years
None
Distal third
(A) 25.2 × 12.7 × 4.37 mm with inner calcification, 15.1 × 8.0 mm volume = 733 mm3
Orally: Propolis 700 mg + bilberry 180 mg + silymarin 400 mg + ginkgo biloba 240 mg + L-carnitine 1000 mg + coenzyme Q-10 100 mg + Boswellia 200 mg + vitamin E 48 mg + vitamin C 50 mg + superoxide dismutase 11,000 IU/g 10 mg/daily/for 44 months + topically diclofenac gel 4%/2 × daily/for 44 months + peri-plaque penile injections pentoxifylline 100 mg (30 G needle) every 2 weeks for 6 months, and then one penile injection every month for 12 months, and then one penile injection every 2 months for 12 months (30 total injections)
IIEF International Index of Erectile Function, VAS visual analogue pain score
×
To obtain informed consent, the patient was notified of the necessary length of treatment owing to the presence of a chronic disease. The patient did not consent to the publication of his penis photos, even if anonymized. Beginning in July 2014, after giving his informed consent, the patient underwent the following treatment: Combined therapy with oral antioxidants propolis 600 mg + bilberry 160 mg + silymarin 400 mg + ginkgo biloba 250 mg + L-carnitine 1000 mg + coenzyme Q10 100 mg + Boswellia 200 mg + vitamin E 30 mg/daily/ + opical diclofenac gel 4%/2 × daily for 12 months.
Oral antioxidants were contained in the following products: Propolifix Plus capsules (propolis + ginkgo biloba), Silifix Plus capsules (silymarin + boswellia + bilberry), Carnitin E Q10 sachets (L-carnitine + coenzyme Q10 + vitamin E).
Anzeige
The patient refused to be treated with penile infiltrations for fear of pain.
Follow-ups were scheduled approximately every 12 months, always confirming the same therapy for each treatment cycle.
After four treatment cycles (each lasting 12 months), the plaque was 99.3% smaller than its initial volume, and the calcification within the plaque was further reduced in size.
Considering the good results, we decided to continue the same treatment for the next 5 months.
After 5 months of antioxidant treatment, and after approximately 4 years and 5 months of multimodal treatment, at follow-up, the IIEF score was 29, penile palpation did not detect any nodule, the two original curvatures were observed to have disappeared, and ultrasound examination no longer showed any plaque (Fig. 6). The multimodal treatment with antioxidants was therefore suspended. The patient did not report any side effects after the treatment.
The patient shared with us satisfaction for the excellent result of the treatment received.
The same ultrasound machine was used at every examination (Philips HD 15) until the follow-up after the third therapy cycle when the ultrasound system in our clinic had been replaced by a new machine (Philips Affinity 70 G). The same doctor performed all ultrasound examinations at every follow-up.
Progressive improvements (plaque volume reduction) after each cycle are shown in Figs. 2, 3, 4, 5, and 6. (See also Table 1).
Fig. 2
Penile ultrasound after the first treatment cycle (12 months). A Plaque measurement in longitudinal and transverse scan. B Calcification measurement in longitudinal scan
Fig. 3
Penile ultrasound after the second treatment cycle (12 months). A Plaque measurement in longitudinal and transverse scan. B Calcification measurement in longitudinal scan
Fig. 4
Penile ultrasound after the third treatment cycle (12 months). A Plaque measurement in longitudinal and transverse scan. B Calcification measurement in longitudinal scan
Fig. 5
Penile ultrasound after the fourth treatment cycle (12 months). A Plaque measurement in longitudinal and transverse scan. B Calcification measurement in longitudinal scan
Fig. 6
Penile ultrasound after the fifth treatment cycle (5 months). A Longitudinal scan. B Transverse scan
×
×
×
×
×
Anzeige
Case 2
A 26-year-old Caucasian man with congenital lateral-right penile curvature (15°) before the onset of PD, presented to our clinic in June 2019; he did not report any penile pain, but complained a worsening of penile curvature with onset about 6 months previously. At the time of our observation, the patient presented a lateral-right penile curvature of 30°. The patient was therefore asked to fill in the IIEF-questionnaire on erectile function, and underwent physical examination and penile Doppler ultrasound (alprostadil 10 mcg). The IIEF score was 28 (normal range 26–30). On penile palpation during physical examination, no nodules were detected. Cavernous artery flow and end-diastolic velocity were normal: peak systolic velocity = 98 cm/seconds on the right and 96 cm/seconds on the left; end-diastolic velocity = 0 cm/seconds bilaterally. The penile plaque, located at the proximal third of the penis, had an iso-hypoechoic appearance, and its dimensions were 10.1 × 7.65 × 3.02 mm, with a volume of 122 mm3 (Fig. 7, see Table 1 at the end of the Case report section).
Fig. 7
Penile ultrasound and plaque measurement prior to treatment (longitudinal and transverse scan).
×
To obtain informed consent, the patient was notified of the necessary length of treatment owing to the presence of a chronic disease. The patient did not consent to the publication of his penis photos, even if anonymized. After receiving the patient’s informed consent, we began the following treatment in July 2019: Combined therapy with oral antioxidants propolis 700 mg + bilberry 180 mg + silymarin 400 mg + ginkgo biloba 240 mg + L-carnitine 1000 mg + coenzyme Q10 100 mg + Boswellia 200 mg + vitamin E 48 mg + vitamin C 50 mg + superoxide dismutase 11,000 IU/g 10 mg/daily + topical diclofenac gel 4%/2 × daily + peri-plaque penile injection of pentoxifylline 100 mg with 30 G needle every month for 12 months.
All oral antioxidants were contained in the following product: Peyflog tablets.
Follow-ups were scheduled approximately every 12 months, always confirming the same therapy for each treatment cycle. Considering the good response to the first multimodal treatment, we decided to schedule a second cycle of oral and topical treatment for 12 months, using the same agents and doses and reducing the frequency of peri-plaque penile injections with pentoxifylline 100 mg to one penile injection every 2 months for 12 months.
Anzeige
At the end of the second cycle of treatment and after 28 months of multimodal treatment, the patient underwent follow-up with physical examination and penile Doppler ultrasound. At follow-up, we observed a further reduction in the angle of the lateral right curve, which measured 15°, similar to the original congenital penile curvature, before the onset of PD. Ultrasound examination no longer showed any plaque (Fig. 9).
Our multimodal treatment with antioxidants was therefore suspended.
The patient shared with us satisfaction for the excellent result of the treatment received.
The patient did not report any side effects after the treatment.
Anzeige
The same ultrasound machine was used at initial presentation and in the follow-up examinations (Philips Affinity 70 G), and the ultrasound examination was always performed by the same doctor.
Progressive improvements (plaque volume reduction) after each cycle are shown in Figs. 8 and 9. (See also Table 1)
Fig. 8
Penile ultrasound after the first treatment cycle (longitudinal and transverse scan)
Fig. 9
Penile ultrasound after the second treatment cycle. A longitudinal scan. B Transverse scan
×
×
Case 3
A 36-year-old Caucasian man with chronic prostatitis, lichen sclerosus, and congenital dorsal penile curvature (10°) presented to our clinic in April 2018, complaining of penile pain during erection within the last 18 months, and new complex penile curvature with onset about 12 months previously. At the time of our observation, the patient presented the penile deformity of both a dorsal curvature with a 15° angle and a lateral left curvature of 20°. The VAS was 5 (score from 0 to 10). The patient was therefore asked to fill in the IIEF-questionnaire on erectile function, and underwent physical examination and penile Doppler ultrasound (alprostadil 10 mcg). The IIEF score was 25 (normal range: 26–30). On palpation, physical examination revealed a nodule measuring about 20 mm in length at the middle third of the penis.
Cavernous artery flow and end-diastolic velocity were normal: peak systolic velocity = 92 cm/seconds (bilaterally), end-diastolic velocity = 0 cm/seconds bilaterally. The penile plaque, located at the middle third of the penis, had a hypo-isohyperechoic appearance and its dimensions were 20.7 × 13.3 × 3.78 mm, with a volume of 543.0 mm3. Within the plaque there was a calcification measuring 4.2 × 3.7 mm (Fig. 10, see Table 1 at the end of the Case report section).
Fig. 10
Penile ultrasound and plaque measurement prior to treatment (longitudinal and transverse scan)
×
To obtain informed consent, the patient was notified of the necessary length of treatment owing to the presence of a chronic disease. The patient did not consent to the publication of his penis photos, even if anonymized. After receiving the patient’s informed consent, we began the following treatment in July 2019: Combined therapy with oral antioxidants propolis 700 mg + bilberry 180 mg + silymarin 400 mg + ginkgo biloba 240 mg + L-carnitine 1000 mg + coenzyme Q10 100 mg + Boswellia 200 mg + vitamin E 48 mg + vitamin C 50 mg + superoxide dismutase 11,000 IU/g 10 mg/daily + topical diclofenac gel 4%/2 × daily + peri-plaque penile injection (pentoxifylline 100 mg) every 2 weeks for 6 months. All oral antioxidants were contained in the following product: Peyflog tablets.
Considering the good response to the first multimodal treatment, we decided to schedule subsequent treatment cycles of oral and topical treatment for 24 months, using the same agents and doses and reducing the frequency of peri-plaque penile injections with pentoxifylline 100 mg to one penile injection every month for 12 months (second cycle) and subsequently, we further reduced the frequency of penile injections to one injection every 2 months for 12 months (third cycle).
Considering the good response to the the third cycle of multimodal treatment, we decided to schedule a fourth treatment cycle with the oral and topical treatment, using the same agents and doses for 6 months, and to suspend the peri-plaque pentoxifylline injections.
After 6 months of oral and topical treatment, the patient underwent the same follow-up. The IIEF score was 26. We observed a dorsal curvature with a 10° angle, similar to the original congenital penile curvature. Palpation no longer detected the presence of the nodule. Ultrasound examination no longer showed any plaque (Fig. 14, Table 1).
The patient was not accurate in meeting the follow-up deadlines, and so after approximately 3 years and 8 months of multimodal therapy with antioxidants, the treatment was suspended. The patient did not report any side effects after the treatment.
The patient shared with us satisfaction for the excellent result of the treatment received.
The same ultrasound machine was used at initial presentation and in the follow-up examinations (Philips Affinity 70 G), and the ultrasound examination was always performed by the same doctor.
Progressive improvements (plaque volume reduction) after each cycle are shown in Figs. 11, 12, 13, and 14. (See also Table 1)
Fig. 11
Penile ultrasound after the first treatment cycle (longitudinal and transverse scan)
Fig. 12
Penile ultrasound after the second treatment cycle (longitudinal and transverse scan)
Fig. 13
Penile ultrasound after the third treatment cycle (longitudinal and transverse scan)
Fig. 14
Penile ultrasound after the fourth treatment cycle. A longitudinal scan. B Transverse scan
×
×
×
×
Discussion
It has been observed in the literature that, following multimodal treatment with antioxidants in patients with PD, there may be a reduction in plaque, as well as an improvement in the corresponding deformity [14‐22].
We know that chronic inflammatory diseases (including PD) are very long lasting, therefore, an adequate period of treatment is required to stop the course of the disease and for progressive reabsorption of the plaque; considering this, the multimodal treatment of PD will necessarily be long (a few years), as described in our case reports.
Probably in Case 1 the treatment was necessarily longer because this patient refused the PTX injections. This is the second article describing the complete plaque regression achieved in human patients with PD [23]. In the literature, there is one experimental study on rats where complete plaque regression has been achieved [24].
Compared with our previous case report, in this article the antioxidant therapy is significantly enhanced, in fact in all three cases new antioxidant substances have been added (L-carnitine, coenzyme Q-10, Boswellia) and specifically in cases 2 and 3, we increased the dosages of two substances (propolis from 600 to 700 mg and bilberry from 160 to 180 mg), and we also added other substances (vitamin C 50 mg + superoxide dismutase 11,000 IU), which allowed us to significantly reduce the dosage of vitamin E.
In addition, in this new article, there is a case report of a patient (Case 2, 26 years old) who had regression of the plaque in a significantly shorter time, most likely due to his younger age. Compared with the older PD patients, younger patients present themselves early to the medical examination, and therefore in an early stage of the disease [25].
In fact, in this case, at the ultrasound study the plaque had an iso-hypoechoic appearance and with smaller dimensions (122 mm3) than all the other cases treated in this article and in the previous case report.
At our Peyronie’s Care Center, we treat many PD patients with similar “combination” therapies. We decide on the most suitable treatment for each patient, taking into account the size of the plaque, the presence of any associated erectile dysfunction, the age of the patients, and their associated risk factors.
Our indications for conservative treatment with multimodal therapy are that Peyronie’s disease is in the active (not stabilized) phase and that the plaque must not be completely calcified.
The associated risk factors (erectile dysfunction, diabetes mellitus, cigarette smoking, arterial hypertension, and so on) require longer treatment to obtain a good result.
In our current experience, we are treating about 50 PD patients with similar multimodal therapy. Other patients (about 15), despite the planned follow-up, showed a reduction in plaque and penile curve, but dropped out of treatment because, in their opinion, it was too long. The negative results we have obtained are from some patients (about 10 cases, owing to important associated risk factors), in whom the cure was longer before obtaining the final result.
Despite the limited number of patients, we believe that this experience is very important and suggestive for all Uro-Andrologists. We think disease regression was made possible by the properties of the antioxidants used. These antioxidants are known to be capable of interrupting the inflammatory process by combating oxidative stress, an essential player in PD pathogenesis. All substances in our combined approach (propolis, bilberry, carnitine, coenzyme Q10, silymarin, ginkgo biloba, vitamin C, vitamin E, and diclofenac) are factor NF-kB inhibitors and block production of proinflammatory cytokines [8, 26‐40]. We believed from the start that topical treatment with diclofenac would be useful in the treatment of PD, for its well-established painkilling and antiinflammatory properties, as well as its free-radical scavenging activity and action against the proinflammatory cytokine cascade, including factor NF-kB production. Diclofenac has also been proven to be capable of being absorbed topically, not just subcutaneously but in subfascial tissues. Radermacher et al. (1991) also proved that topical diclofenac gel is able to penetrate into the articular capsule of the knee, which is much thicker than the tunica albuginea of the penis [41].
Throughout our entire treatment, the oral and topical therapy did not vary. In cases 2 and 3, at each subsequent treatment cycle, the frequency of peri-plaque injections with PTX 100 mg was gradually reduced. This decision was based on the fact that disease progression had already stopped after the first cycle of treatment, and signs of partial regression were observed on physical examination and diagnostic imaging. Furthermore, as trauma is undoubtedly at the origin of PD and even micro-injuries may bear serious consequences in genetically predisposed patients, even injections must be considered a source of microtrauma for the tissues, therefore we made sure to use a very thin needle when performing the injections in the area around the plaque, and we decreased the number of injections at every treatment cycle.
In the literature, ultrasound imaging of PD has been described by many as being incapable of providing accurate plaque measurements [42]. On the contrary, we believe that an ultrasound examination performed with a cutting-edge ultrasound machine by a highly experienced operator with extensive knowledge of the disease can provide a measurement of the plaque that is very helpful to assess patients at presentation and to accurately evaluate treatment outcome at follow-up [43, 44].
Conclusion
Many urologists think that Peyronie’s disease is an incurable disease, as some authors have written. The result is a renunciative therapeutic attitude of many urologists. Despite the limited number of patients, this study shows that a multimodal combined antioxidant treatment can yield good outcomes. Hence, PD can be cured.
In addition to the multimodal treatment, we believe a key element is a correct ultrasound assessment performed with a state-of-the-art ultrasound machine by a highly experienced operator.
We have decided to publish this experience in spite of its limited size, as we think the outcomes achieved with our multimodal therapy with combined antioxidants in these patients may prove useful in urology and andrology practice, and we would welcome randomized controlled studies being carried out in the future to investigate the effectiveness of this treatment in a larger number of PD patients.
Acknowledgments
We thank Dr. Pasquale Del Vecchio for bibliometric and data management analysis.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for Publication
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Competing Interests
The authors have no conflicts of interest to declare.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
